

**17**

with water or an aqueous solvent to obtain an extract solution and the extract solution is dried to obtain a drug extract in powder form.

**10.** A method as claimed in claim **9** wherein the pH of said water or aqueous solvent for extraction is adjusted to 8.5 to 10.5.

**11.** A method as claimed in claim **8** wherein the amount of soluble silicon is determined by dissolving the dry drug extract in water to an extent of 1 mg/mL, removing insoluble matter to obtain an aqueous solution, and determining the amount of the silicon in said aqueous solution.

**12.** A method as claimed in claim **11** wherein the drug extracts are standardized for pharmaceutical effectiveness as

**18**

an anti-allergic agent, an analgesic agent, or an anti-inflammatory agent.

**13.** A method for evaluating the inhibiting activity of plant drug extracts against plasma kallikrein production comprising:

determining the amount of soluble silicon compounds calculated as silicon per gram of dry drug extract; and comparing the determined amount of soluble silicon compounds to a minimal amount needed to obtain inhibition of plasma kallikrein production.

\* \* \* \* \*